|
| | | | | | | | | | | | |
| Name | Indication | Approval | MOA | Economics | Admin | IP | | | Price | 232.86 | |
| Onpattro (patisiran) | ATTR Polyneuropathy | | TTR | ABUS? | IV | | | | Shares | 122.991 | Q322 |
| Givlaari (givosiran) | | | | | | | | | MC | 28639.68426 | |
| Oxlumo (lumasiran) | PH1 | 11/1/2020 | HAO1 | | Subcutaneous | | | | Cash | 2314.7180000000003 | Q322 |
| Leqvio (inclisiran) | Hypercholesterolemia | | PCSK9 | NVS | Subcutaneous | | | | Debt | 2247.848 | Q322 |
| Amvuttra (vutrisiran) | ATTR Polyneuropathy | | TTR | | Subcutaneous | | | | EV | 28572.81426 | |
| | | Phase | | | | | | | | | |
| cemdisiran | IgAN | | | | | | | | | | |
| fitusiran | Hemophilia | | | | | | | HQ: Cambridge, MA | | | |
| zilebesiran | | | | | | | | VP, Global Rare Disease Lead: Jorge Capapey | | | |
| ALN-APP | Alzheimer's, CAA | | | | | | | TTR Lead: Rena N. Denoncourt | | | |
| ALN-XDH | Gout | | | | | | | CEO: Yvonne Greenstreet | | | |
| ALN-HSD | NASH | HSD17B3 | I | REGN | | | | CDSO: Evan Lippman | | | |
| | NASH | PNPLA3 | PC | REGN | | | | SVP, Head International Region: Kasha Witkos | | | |
| | NASH | CIDEB | PC | REGN | | | | | | | |
| | | | | | | | | | | | |
| | | | | | 10/13/22: Q3 results date | | | | | | |
| | | | | | 10/6/22: sNDA approved for Oxlumo in PH1 | | | | | | |
| | | | | | 9/30/22: APOLLO-B presentation at HFS (incomplete) | | | | | | |
| | | | | | 9/21/22: Management changes | | | | | | |
| | | | | | 9/20/22: Amvuttra approved in EU | | | | | | |
| | | | | | 9/19/22: RNAi roundtable webcast | | | | | | |
| | | | | | 9/15/22: ALN-HSD Phase I results | | | | | | |
| | | | | | 9/13/22: to present APOLLO-B at HFS | | | | | | |
| | | | | | 9/13/22: prices $900m converts | | | | | | |
| | | | | | 9/12/22: to sell $900m converts | | | | | | |